Loredana Salerno
Overview
Explore the profile of Loredana Salerno including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Virzi N, Alvarez-Lorenzo C, Concheiro A, Consoli V, Salerno L, Vanella L, et al.
Int J Pharm
. 2024 Nov;
668:124997.
PMID: 39586511
Heme oxygenase-1 (HO-1) has been identified as a potential new target in anticancer therapy, being overexpressed in different tumors and crucial for cell proliferation. Advances in the development of specific...
2.
Consoli V, Fallica A, Virzi N, Salerno L, Intagliata S, Sorrenti V, et al.
ACS Med Chem Lett
. 2024 May;
15(5):706-713.
PMID: 38746881
Herein, we describe the design, synthesis, and in vitro biological evaluation of HO-1 inducers endowed with cytotoxic effects mediated by ferroptosis activation. Using the natural HO-1 inducer caffeic acid phenethyl...
3.
Salerno L, Notaro A, Consoli V, Affranchi F, Pittala V, Sorrenti V, et al.
J Enzyme Inhib Med Chem
. 2024 Apr;
39(1):2337191.
PMID: 38634597
Colon cancer remains a clinical challenge in industrialised countries. Its treatment with 5-Flurouracil (5-FU) develops many side effects and resistance. Thus, several strategies have been undertaken so far, including the...
4.
Suarez-Rojas I, Perez-Fernandez M, Bai X, Martinez-Martel I, Intagliata S, Pittala V, et al.
Antioxidants (Basel)
. 2023 Oct;
12(10).
PMID: 37891937
Neuropathic pain is a type of pain that persists for a long time and becomes pathological. Additionally, the anxiodepressive disorders derived from neuropathic pain are difficult to palliate with the...
5.
Perez-Fernandez M, Suarez-Rojas I, Bai X, Martinez-Martel I, Ciaffaglione V, Pittala V, et al.
Antioxidants (Basel)
. 2023 Oct;
12(10).
PMID: 37891874
Chronic pain caused by persistent inflammation is current in multiple diseases and has a strong negative impact on society. It is commonly associated with several mental illnesses, which can exert...
6.
Salerno L, Sorrenti V, Pittala V, Consoli V, Modica M, Romeo G, et al.
ChemMedChem
. 2023 Feb;
18(8):e202300047.
PMID: 36756924
In this work, we extend the concept of 5-fluorouracil/heme oxygenase 1 (5-FU/HO-1) inhibitor hybrid as an effective strategy for enhancing 5-FU-based anticancer therapies. For this purpose, we designed and synthesized...
7.
Nesic de Freitas L, da Silva C, Intagliata S, Amata E, Salerno L, Soeiro M
Parasitology
. 2023 Jan;
150(4):359-364.
PMID: 36632017
Chagas disease (CD) is a neglected tropical disease caused by the intracellular protozoan that remains a serious public health issue affecting more than 6 million people worldwide. The available treatment...
8.
Fallica A, Ciaffaglione V, Modica M, Pittala V, Salerno L, Amata E, et al.
Bioorg Med Chem
. 2022 Oct;
73:117032.
PMID: 36202063
The overexpression of σ receptors (σRs) in various types of tumors has prompted a deep investigation of their role in cancer pathophysiology. Consequently, σR ligands have been widely studied in...
9.
Ciaffaglione V, Consoli V, Intagliata S, Marrazzo A, Romeo G, Pittala V, et al.
Molecules
. 2022 May;
27(10).
PMID: 35630697
This paper reports on a novel series of tyrosine kinase inhibitors (TKIs) potentially useful for the treatment of chronic myeloid leukemia (CML). The newly designed and synthesized compounds are structurally...
10.
Consoli V, Sorrenti V, Pittala V, Greish K, DAmico A, Romeo G, et al.
Int J Mol Sci
. 2022 May;
23(10).
PMID: 35628518
The term ferroptosis refers to a peculiar type of programmed cell death (PCD) mainly characterized by extensive iron-dependent lipid peroxidation. Recently, ferroptosis has been suggested as a potential new strategy...